Atogepant Superior for Efficacy, Functional Measures in Migraine

THURSDAY, Dec. 26, 2024 (HealthDay News) — For adults with migraine, atogepant 60 mg once daily was superior to placebo for efficacy and functional measures of treatment across three trials, according to research published online Dec. 23 in Neurology.

Richard B. Lipton, M.D., from the Albert Einstein College of Medicine in Bronx, New York, and colleagues examined improvements in efficacy and functional outcomes in the first four weeks of treatment with atogepant 60 mg once daily for the preventive treatment of migraine. The atogepant and placebo treatment arms from three phase 3, multicenter, randomized trials were included (ADVANCE [222 participants with episodic migraine receiving atogepant and 214 receiving placebo]; ELEVATE [151 participants with episodic migraine receiving atogepant and 154 receiving placebo]; and PROGRESS [256 participants with chronic migraine receiving atogepant and 246 receiving placebo]).

The researchers observed greater reductions in the proportion of atogepant-treated participants with a migraine day on day 1. Compared with placebo, the odds ratios were 0.39, 0.53, and 0.63 in ADVANCE, ELEVATE, and PROGRESS, respectively. Reductions in weekly migraine days at weeks 1 to 4 and in monthly migraine days in the first four weeks were seen with atogepant treatment; in addition, at all assessed time points for weeks 1 to 4, Activity Impairment in Migraine-Diary and European Quality-of-Life 5-Dimension 5-Level scores improved compared with placebo.

“The analyses reported here demonstrate the early efficacy and functional improvements of atogepant and address a key unmet need of providing preventive treatment options with early benefits across the spectrum of migraine disease state severity,” the authors write.

Several authors disclosed ties to pharmaceutical companies, including AbbVie, which manufactures atogepant and funded the study.

Abstract/Full Text